Novanta Inc.

Valuation Analysis

About the Company

Novanta Inc., together with its subsidiaries, provides precision medicine, precision manufacturing, medical solutions, robotics and automation solutions, and advanced surgery solutions in the United States and internationally. The company operates Automation Enabling Technologies and Medical Solutions segments. The Precision Medicine and Manufacturing segment designs, manufactures, and markets laser beam steering and scanning solutions, laser sources, robotic and precision motion, robotic end-of-arm tooling, and bearing spindles. This segment serves advanced industrial processes, advanced industrial and medical robotics, other medical and life science automation applications, and medical laser procedures, such as ophthalmology applications. The Medical Solutions segment provides a range of

Novanta Inc. Stock at a Glance

Novanta Inc. (NOVT) is currently trading at $160.53 with a market capitalization of $5.7B. The trailing P/E ratio stands at 114.66x, with a forward P/E of 38.74x. The 52-week range spans from $98.27 to $171.85; the current price is 6.6% below the yearly high. Year-over-year revenue growth stands at +10.4%. The net profit margin stands at 5.35%.

💰 Dividend

Novanta Inc. currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Analyst Rating

2 analysts rate Novanta Inc. (NOVT) on consensus: Strong Buy. The average price target is $175.00, implying +9.01% from the current price. Analyst price targets range from $170.00 to $180.00.

Novanta Inc.: The Investment Case in Detail

Novanta Inc. (NOVT) operates in the Technology — specifically Scientific & Technical Instruments — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

The Bull Case

Revenue is growing at a healthy 10.4% pace year-over-year, suggesting the business model continues to find new customers and pricing power.

The Bear Case

A trailing P/E above 50 combined with revenue growth below 20% is a dangerous combination — the market is paying a steep growth multiple for what is, by the data, only moderately fast expansion. Short interest sits at 13.76% of float — a meaningful contingent of professionals is positioned for the share to fall, which deserves attention even if their thesis may turn out to be wrong. Our valuation screen flags the stock as overvalued — current multiples imply the business needs to deliver well above its recent trajectory to justify the price.

Valuation in Context

The EV/EBITDA multiple of 31.43x reflects rich expectations — historically, multiples at this level have proven hard to maintain for more than a few quarters.

What to Watch Next

• The forward P/E of 38.74x is meaningfully below the trailing 114.66x — analysts expect earnings to step up; the next earnings release is the test.

Investment Thesis: Strengths & Weaknesses

Technical Snapshot

Price trades above both the 50- and 200-day moving averages, with 50d above 200d — a classic bullish setup (golden-cross alignment).

Risk Profile

The data points to above-average price swings, elevated short interest (13.76%).

Trading Data

Related Stocks in the Same Sector

Where can I buy Novanta Inc.?

Compare top-rated brokers — low fees, trusted providers, fully regulated.